COMMUNIQUÉS West-GlobeNewswire

Beleave Announces $5 Million Non-Brokered Private Placement of Units
20/11/2017
TORONTO, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. (" Beleave " or the " Company ") (CSE:BE) (OTCQX:BLEVF) is pleased to announce its intention to complete a non-brokered private placement (the " Non-Brokered [...]
THC Therapeutics in Partnership With ADVFN Announces Formation of New Company - MJAC Investorshub International Conferences Ltd
20/11/2017
LAS VEGAS, Nov. 20, 2017 (GLOBE NEWSWIRE) -- THC Therapeutics, Inc., Inc. (OTC:THCT) (“THCT” or the “Company”) announces that it has formed “MJAC InvestorsHub International Conferences Limited” (“MJAC LTD”) with ADVFN [...]
Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients with DMD in PhaseOut DMD Clinical Trial
20/11/2017
Summit Therapeutics plc ("Summit" or the "Company") SUMMIT COMPLETES INITIAL 24 WEEKS OF DOSING OF EZUTROMID IN PATIENTS WITH DMD IN PhaseOut DMD CLINICAL TRIAL Summit Continues to Expect 24-week Data Q1 2018, which [...]
Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
20/11/2017
WALTHAM, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH ) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced [...]
Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical Trial
20/11/2017
OXFORD, United Kingdom, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Summit Continues to Expect 24-week Data Q1 2018, which Could Provide Potential Proof of Mechanism for Ezutromid Oxford, UK, 20 November 2017 – Summit [...]
Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference
20/11/2017
CARMIEL, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE: PLX ) announced today two-year results from the phase I/II open-label extension clinical trial of [...]
Recro Pharma Secures $100 Million Credit Facility
20/11/2017
Proceeds Provide Funding for IV Meloxicam 30mg Approval Milestone Interest-only Structure Allows for Reinvestment of CDMO Cash Flows in Value Accretive Commercial Activities Substantial Reduction in the Company’s Cost [...]
ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting
20/11/2017
– Controlled IL-12 gene therapy turns cold tumors hot – – MRI indicates decreasing size of brain tumor lesions in several patients – – Median overall survival for patients with recurrent glioblastoma (rGBM) maintained [...]
TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
20/11/2017
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status Approval supported by robust data from a randomized, well-controlled Phase 3 [...]
ProQR Announces Results for the Third Quarter of 2017
20/11/2017
Key updates Runway into the second half of 2019: cash of €39.7 million at end of Q3, increased by gross proceeds of approximately $20 million from an issuance of ordinary shares in November 2017 that will fund [...]
Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
20/11/2017
GAITHERSBURG, Md., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ( [...]
Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency
20/11/2017
Following Kamada’s Recent Withdrawal of European Marketing Authorization Application, Distribution Agreement Not Currently Warranted REHOVOT, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA ) (TASE: [...]
Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia
20/11/2017
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]
Amphastar Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
20/11/2017
RANCHO CUCAMONGA, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH ) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 29th Annual Piper [...]
Orphazyme A/S: Completion of the Offering and registration of share capital increase
20/11/2017
Company announcement No. 12/2017 Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 20 November 2017 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART [...]
TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting
20/11/2017
PRESS RELEASE TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting Leuven (BELGIUM) - November 20, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced [...]
TiGenix présentera les données favorables de la semaine 52 de l'essai de phase III de Cx601 à l'occasion de l'EHA-SWG Scientific Meeting
20/11/2017
COMMUNIQUÉ DE PRESSE TiGenix présentera les données favorables de la semaine 52 de l'essai de phase III de Cx601 à l'occasion de l'EHA-SWG Scientific Meeting Louvain (BELGIQUE) - 20 novembre 2017, 07h. CET - TiGenix NV [...]
Veritas’ Research Arm Cannevert Therapeutics Signs Letter of Intent with Fundación de Investigación (FDI) of Puerto Rico USA to Begin Human Trials of Its Lead Cannabis Strain for Pain
20/11/2017
VANCOUVER, British Columbia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ), (“Veritas” or the “Company”) announces that its research arm, Cannevert Therapeutics Ltd. ("CTL [...]
Orphazyme A/S: No termination or withdrawal of Orphazyme's IPO
20/11/2017
Company announcement No. 11/2017 Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 20 November 2017 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART [...]

Pages